Poroikov, Vladimir

QSAR without borders

Muratov, E. N., Bajorath, J., Sheridan, R. P., Tetko, I. V., Filimonov, D., Poroikov, V., Oprea, T. I., Baskin, I. I., Varnek, A., Roitberg, A., et al. (2020) · Chemical Society Reviews

Computational Drug Discovery MethodsMachine Learning in Materials Science

Cited by 913

A critical overview of computational approaches employed for COVID-19 drug discovery

Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., Isayev, O., Kozakov, D., Medina-Franco, J. L., Merz, K. M., et al. (2021) · Chemical Society Reviews

Computational Drug Discovery MethodsSARS-CoV-2 and COVID-19 Research

Cited by 206

Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS

Lagunin, A., Filimonov, D., & Poroikov, V. (2010) · Current Pharmaceutical Design

Computational Drug Discovery MethodsBioactive natural compounds

Cited by 179

In silico assessment of adverse drug reactions and associated mechanisms

Ivanov, S. M., Lagunin, A. A., & Poroikov, V. V. (2016) · Drug Discovery Today

Computational Drug Discovery MethodsPharmacovigilance and Adverse Drug Reactions

Cited by 49

How to Achieve Better Results Using PASS-Based Virtual Screening: Case Study for Kinase Inhibitors

Pogodin, P. V., Lagunin, A. A., Rudik, A. V., Filimonov, D. A., Druzhilovskiy, D. S., Nicklaus, M. C., & Poroikov, V. V. (2018) · Frontiers in Chemistry

Computational Drug Discovery MethodsSynthesis and Characterization of Heterocyclic Compounds

Cited by 40

QSAR Modeling Using Large-Scale Databases: Case Study for HIV-1 Reverse Transcriptase Inhibitors

Tarasova, O. A., Urusova, A. F., Filimonov, D. A., Nicklaus, M. C., Zakharov, A. V., & Poroikov, V. V. (2015) · Journal of Chemical Information and Modeling

Computational Drug Discovery MethodsMachine Learning in Materials Science

Cited by 39